The UCL Campus (encompassing UCLH and GOSH) has the largest CAR T-cell programme in Europe and one of the largest globally. The campus currently has 10 studies open which use technology used at UCL. Many of the studies are academic, but several are funded and sponsored by industrial partners.
|COBALT||NCT02431988||Anti-CD19 CAR T-cell therapy for relapsed / refractory Diffuse Large B-cell Lymphoma.||Bloodwise / UCL||Completed|
|CARD||NCT02893189||Haematopoietic stem cell transplant donor derived CAR T-cells for relapsed / refractory B-cell malignancy. One of the first studies to utilized automated CAR T-cell manufacture.||EU Framework 7 ATECT Consortium||Completed|
|CARPALLv1||NCT02443831||This study tests a new type of CD19 CAR (CAT-41BB-z) with a fast binding kinetic which is designed to reduce toxicity in paediatric and young adults with relapsed / refractory B-cell acute lymphoblastic leukemia (B-ALL).||Children With Cancer / UCL|
Completed. Study shows excellent safety and engraftment profile of CAT-41BB-Z receptor. Study findings published: Ghorashian et al, Nat Med 2019 Sep;25(9):1408-1414
|ALLCAR19v1||NCT02935257||This is a sister study to CARPALL and tests CAT-41BB-Z in adults with relapsed / refractory B-ALL.||NIHR / UCL|
Completed. Study confirms excellent safety and engraftment profile of CAT-41BB-Z in 20 patients. Study findings published: Roddie et al, JCO, doi: 10.1200/JCO.21.00917.
Note: phase II registration study (Felix): NCT04404660.
|UCART19||NCT02808442||This is the first test of gene-edited CAR T-cells. This study tests allogeneic ,off-the-shelf, CD19 CAR T-cells for relapsed B-ALL. See Qasim et al, Sci Transl Med. 2017 Jan 25;9(374).||Cellectis/Cellectis||Completed. Study published by Benjamin et al, Lancet, 2020 Dec 12;396(10277):1885-1894.|
|1RG-CART||NCT02761915||Autologous CAR T-cell targeting of GD2 for children with relapsed / refractory neuroblastoma.||CRUK/CRUK|
Completed. This study showed anti-tumour activity and immune effects of GD2 CAR. Study findings published: Straathof et al, Sci Transl Med 2020 Nov 25;12(571).
|AUTO-02||NCT03287804||Anti-BCMA/TACI CAR T-cell therapy for refractory multiple myeloma. See Lee et al, Blood. 2018 Feb 15;131(7):746-758.||AUTOLUS/AUTOLUS||Completed.|
|AUTO-03 AMELIA||NCT03289455||This study tests a bi-cistronic CAR cassette which co-expresses a CD19 CAR and a CD22 CAR (AUTO-03) with the aim of preventing relapse due to down-regulation of CD19. AMELIA tests AUTO-03 in paediatric relapsed / refractory B-ALL.||AUTOLUS/AUTOLUS||Completed.|
|AUTO-03 ALEXANDER||NCT03287817||ALEXANDER tests AUTO-03 in patients with relapsed / refractory DLBCL in combination with PD1 blockade.||AUTOLUS/AUTOLUS||Completed.|
|AUTO-04||NCT03590574||Tests a new way to target T-cell lymphomas by targeting one isoform of the T-cell receptor. See Maciocia et al, Nat Med. 2017 Dec;23(12):1416-1423.||AUTOLUS/AUTOLUS||Recruiting.|
|CAROUSEL||NCT04443829||Tests CAT19 in Primary CNS Lymphoma. Both intravenous and intra-ventricular routes of administration are tested.||Wellcome Trust / UCL||Recruiting.|
|NCT02443831||This is a continuation of the CARPALL study. Since the main mode of relapse was CD19 negative escape, the product has been modified by co-transduction with a highly sensitive CD22 CAR (9A8-41BB-Z).||Autolus / UCL||Recruiting.|
This is a continuation of the ALLCAR19 study as a major amendment. The same therapeutic product is being tested in three additional cohors:
|Autolus / UCL|
An update was presented by Dr Roddie at EHA 2021, abstract #EP788
|MCARTY||Tests a high-sensitivity Fab BCMA CAR (D8Fab-41BB-Z) in patients with refractory Myeloma. An additional cohort of patients will receive T cells co-transduced with CAT-41BB-Z. CAR T cells will be manufactured in AKTiVIII.||AUTOLUS/UCL||Regulatory|
|Tests a novel approach for generating allogeneic CAR T cells without genome editing||MRC/UCL||Scale-up|
|EGFRvIII CAR T cell therapy with||Moulton/UCL||Scale-up|
|DMGRA2||Q3 2021||Multi-modular IL13RA CAR T cell therapy for Diffuse Midline Glioma||Moulton & Abbie's Army/UCL||Pre-clinical|
|Multi-edited CD30 CAR T cell therapy for refractory Hodgkin Disease||Moulton/UCL||Pre-clinical|
|MCARGD2||Q4 2021||Multi-modular GD2 CAR T cell therapy for relapsed / refractory Neuroblastoma||Autolus/UCL||Scale-up|